High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
The voltage-gated potassium channel Kv1.5 is one of the key regulators of membrane potential repolarization in human atrial myocytes and is considered a potential drug target to treat atrial fibrillation. In this study we sought to determine molecular mechanism of action of DPO-1, a diphenylphosphine oxide derivative recently shown to terminate experimental atrial arrhythmia without affecting ventricular refractory period. In addition, we provided similar analysis for additional two small molecule blockers, representing different structural classes: cyclohexanones (PAC) and nor-triterpenoids (correolide). To rapidly identify the residues within the Kv1.5 channel critical for blocking activity of these molecules, two functional high-throughput ion channel assays were employed together with site-directed mutagenesis. Our study revealed that the residues critical for blocking activity of for DPO-1 include T480, localized at the outer mouth of the pore, and two residues along S6 helix: V505 and I508. The overlapping site was identified for PAC and included residues T480 and V505. In contrast to DPO-1, the I508A mutation resulted in only a modest reduction in the block of Kv1.5 by PAC (9-fold). Correolide, the largest molecule examined, made widespread interactions along the entire length of the pore (from T480 to V516). In summary, we have identified multiple residues involved in forming high affinity binding site for Kv1.5 blockers. Similar approaches of high-throughput ion channel technologies, combined with site-directed mutagenesis, may allow for parallel, rapid and accurate analysis of ion channel interactions with multiple compounds and could facilitate the design of more potent and selective ion channel blockers.
Karczewski
Jerzy
J
Department of Pain Research, Merck Research Laboratories, West Point, PA 19486, USA. jerzy_karczewski@merck.com
Kiss
Laszlo
L
Kane
Stefanie A
SA
Koblan
Kenneth S
KS
Lynch
Robert J
RJ
Spencer
Robert H
RH
D000818:Animals; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000503:physiopathology; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D003512:Cyclohexanones / Q000494:pharmacology*; D004546:Elapid Venoms / Q000494:pharmacology; D004594:Electrophysiology / Q000379:methods; D006801:Humans; D007700:Kinetics; D051666:Kv1.5 Potassium Channel / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D016297:Mutagenesis, Site-Directed; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000502:physiology; D018408:Patch-Clamp Techniques; D010720:Phosphines / Q000494:pharmacology* / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D012413:Rubidium / Q000378:metabolism; D013054:Spectrophotometry, Atomic; D014315:Triterpenes / Q000494:pharmacology
C507236:(2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide; D003512:Cyclohexanones; D004546:Elapid Venoms; D051666:Kv1.5 Potassium Channel; D010720:Phosphines; D014315:Triterpenes; C118657:correolide; C020273:dendrotoxin; D012413:Rubidium